{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:57:25Z","timestamp":1791233845407,"version":"4.1.0"},"reference-count":52,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2015,5,12]],"date-time":"2015-05-12T00:00:00Z","timestamp":1431388800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0125482","type":"journal-article","created":{"date-parts":[[2015,5,12]],"date-time":"2015-05-12T17:50:25Z","timestamp":1431453025000},"page":"e0125482","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":105,"title":["A Synthetic Lethal Screen Identifies DNA Repair Pathways that Sensitize Cancer Cells to Combined ATR Inhibition and Cisplatin Treatments"],"prefix":"10.1371","volume":"10","author":[{"given":"Kareem N.","family":"Mohni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petria S.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica W.","family":"Luzwick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloria G.","family":"Glick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher S.","family":"Pendleton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian D.","family":"Lehmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer A.","family":"Pietenpol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Cortez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2015,5,12]]},"reference":[{"issue":"Suppl 1","key":"ref1","doi-asserted-by":"crossref","first-page":"E16","DOI":"10.3816\/CBC.2010.s.003","article-title":"Novel treatment approaches for triple-negative breast cancer","volume":"10","author":"ML Telli","year":"2010","journal-title":"Clinical breast cancer"},{"issue":"2","key":"ref2","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s10549-010-1248-6","article-title":"Aberrant expression of DNA damage response proteins is associated with breast cancer subtype and clinical features","volume":"129","author":"G Guler","year":"2011","journal-title":"Breast Cancer Res Treat"},{"issue":"19","key":"ref3","doi-asserted-by":"crossref","first-page":"4702","DOI":"10.1158\/1078-0432.CCR-10-0939","article-title":"Poly(ADP-Ribose) polymerase inhibition: &quot;targeted&quot; therapy for triple-negative breast cancer","volume":"16","author":"CK Anders","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"7417","key":"ref4","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/nature11404","article-title":"Comprehensive genomic characterization of squamous cell lung cancers","volume":"489","year":"2012","journal-title":"Nature"},{"issue":"3","key":"ref5","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/nrclinonc.2012.3","article-title":"The potential of exploiting DNA-repair defects for optimizing lung cancer treatment","volume":"9","author":"S Postel-Vinay","year":"2012","journal-title":"Nature reviews Clinical oncology"},{"issue":"Suppl 1","key":"ref6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1634\/theoncologist.2011-S1-01","article-title":"Triple-negative breast cancer: an unmet medical need","volume":"16","author":"CA Hudis","year":"2011","journal-title":"The oncologist"},{"issue":"3","key":"ref7","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/nrclinonc.2009.234","article-title":"Management of breast cancer with targeted agents: importance of heterogeneity. [corrected]","volume":"7","author":"S Di Cosimo","year":"2010","journal-title":"Nature reviews Clinical oncology"},{"issue":"6","key":"ref8","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/j.ejca.2012.11.021","article-title":"Systemic therapy of advanced non-small cell lung cancer: major-developments of the last 5-years","volume":"49","author":"T Cufer","year":"2013","journal-title":"Eur J Cancer"},{"issue":"8","key":"ref9","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/nrm2450","article-title":"ATR: an essential regulator of genome integrity","volume":"9","author":"KA Cimprich","year":"2008","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"3","key":"ref10","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/nrg2268","article-title":"Genome instability: a mechanistic view of its causes and consequences","volume":"9","author":"A Aguilera","year":"2008","journal-title":"Nature reviews Genetics"},{"issue":"3","key":"ref11","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1038\/nrm2852","article-title":"Maintaining genome stability at the replication fork","volume":"11","author":"D Branzei","year":"2010","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"7035","key":"ref12","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1038\/nature03482","article-title":"DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis","volume":"434","author":"J Bartkova","year":"2005","journal-title":"Nature"},{"issue":"7035","key":"ref13","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1038\/nature03485","article-title":"Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions","volume":"434","author":"VG Gorgoulis","year":"2005","journal-title":"Nature"},{"issue":"56","key":"ref14","doi-asserted-by":"crossref","first-page":"7773","DOI":"10.1038\/sj.onc.1210881","article-title":"DNA damage signalling guards against activated oncogenes and tumour progression","volume":"26","author":"J Bartek","year":"2007","journal-title":"Oncogene"},{"issue":"7","key":"ref15","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1021\/jm101488z","article-title":"Discovery of potent and selective inhibitors of ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase as potential anticancer agents","volume":"54","author":"JD Charrier","year":"2011","journal-title":"J Med Chem"},{"issue":"14","key":"ref16","doi-asserted-by":"crossref","first-page":"5674","DOI":"10.18632\/oncotarget.2158","article-title":"Potentiation of tumor responses to DNA damaging therapy by the selective ATR inhibitor VX-970","volume":"5","author":"AB Hall","year":"2014","journal-title":"Oncotarget"},{"issue":"5","key":"ref17","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1021\/jm301859s","article-title":"Discovery of 4-{4-[(3R)-3-Methylmorpholin-4-yl]-6-[1-(methylsulfonyl)cyclopropyl]pyrimidin-2-y l}-1H-indole (AZ20): a potent and selective inhibitor of ATR protein kinase with monotherapy in vivo antitumor activity","volume":"56","author":"KM Foote","year":"2013","journal-title":"J Med Chem"},{"issue":"10","key":"ref18","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1158\/0008-5472.CAN-13-3229","article-title":"ATR pathway inhibition is synthetically lethal in cancer cells with ERCC1 deficiency","volume":"74","author":"KN Mohni","year":"2014","journal-title":"Cancer Res"},{"issue":"7","key":"ref19","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/nchembio.573","article-title":"Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR","volume":"7","author":"PM Reaper","year":"2011","journal-title":"Nature chemical biology"},{"issue":"2","key":"ref20","doi-asserted-by":"crossref","first-page":"e57098","DOI":"10.1371\/journal.pone.0057098","article-title":"Ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase inhibition is synthetically lethal in XRCC1 deficient ovarian cancer cells","volume":"8","author":"R Sultana","year":"2013","journal-title":"PLoS One"},{"issue":"6","key":"ref21","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/nsmb.2076","article-title":"A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations","volume":"18","author":"LI Toledo","year":"2011","journal-title":"Nat Struct Mol Biol"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"e441","DOI":"10.1038\/cddis.2012.181","article-title":"Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation","volume":"3","author":"E Fokas","year":"2012","journal-title":"Cell death & disease"},{"issue":"4","key":"ref23","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.cell.2011.03.041","article-title":"Double-strand break repair-independent role for BRCA2 in blocking stalled replication fork degradation by MRE11","volume":"145","author":"K Schlacher","year":"2011","journal-title":"Cell"},{"issue":"16","key":"ref24","first-page":"4308","article-title":"Human chromosome 3 corrects mismatch repair deficiency and microsatellite instability and reduces N-methyl-N&apos;-nitro-N-nitrosoguanidine tolerance in colon tumor cells with homozygous hMLH1 mutation","volume":"54","author":"M Koi","year":"1994","journal-title":"Cancer Res"},{"issue":"18","key":"ref25","first-page":"3949","article-title":"Correction of hypermutability, N-methyl-N&apos;-nitro-N-nitrosoguanidine resistance, and defective DNA mismatch repair by introducing chromosome 2 into human tumor cells with mutations in MSH2 and MSH6","volume":"57","author":"A Umar","year":"1997","journal-title":"Cancer Res"},{"issue":"18","key":"ref26","doi-asserted-by":"crossref","first-page":"5003","DOI":"10.1158\/1078-0432.CCR-13-1391","article-title":"BMN 673, a novel and highly potent PARP1\/2 inhibitor for the treatment of human cancers with DNA repair deficiency","volume":"19","author":"Y Shen","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"14","key":"ref27","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1101\/gad.214080.113","article-title":"ATR phosphorylates SMARCAL1 to prevent replication fork collapse","volume":"27","author":"FB Couch","year":"2013","journal-title":"Genes Dev"},{"issue":"4\u20135","key":"ref28","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/0166-3542(90)90001-N","article-title":"A three-dimensional model to analyze drug-drug interactions","volume":"14","author":"MN Prichard","year":"1990","journal-title":"Antiviral Res"},{"issue":"2","key":"ref29","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0031-6997(25)06847-4","article-title":"The search for synergy: a critical review from a response surface perspective","volume":"47","author":"WR Greco","year":"1995","journal-title":"Pharmacological reviews"},{"issue":"2","key":"ref30","first-page":"477","article-title":"Antagonists of nucleic acid derivatives. VIII. Synergism in combinations of biochemically related antimetabolites","volume":"208","author":"GB Elion","year":"1954","journal-title":"J Biol Chem"},{"issue":"19","key":"ref31","doi-asserted-by":"crossref","first-page":"7139","DOI":"10.1158\/0008-5472.CAN-04-1289","article-title":"ATR affecting cell radiosensitivity is dependent on homologous recombination repair but independent of nonhomologous end joining","volume":"64","author":"H Wang","year":"2004","journal-title":"Cancer Res"},{"issue":"7035","key":"ref32","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/nature03443","article-title":"Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase","volume":"434","author":"HE Bryant","year":"2005","journal-title":"Nature"},{"issue":"7035","key":"ref33","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nature03445","article-title":"Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy","volume":"434","author":"H Farmer","year":"2005","journal-title":"Nature"},{"issue":"21","key":"ref34","doi-asserted-by":"crossref","first-page":"5588","DOI":"10.1158\/0008-5472.CAN-12-2753","article-title":"Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors","volume":"72","author":"J Murai","year":"2012","journal-title":"Cancer Res"},{"issue":"9","key":"ref35","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1038\/emboj.2008.61","article-title":"A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor","volume":"27","author":"NC Turner","year":"2008","journal-title":"EMBO J"},{"issue":"12","key":"ref36","doi-asserted-by":"crossref","first-page":"3683","DOI":"10.1158\/0008-5472.CAN-13-0110","article-title":"ATR inhibition broadly sensitizes ovarian cancer cells to chemotherapy independent of BRCA status","volume":"73","author":"CJ Huntoon","year":"2013","journal-title":"Cancer Res"},{"issue":"8","key":"ref37","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.dnarep.2010.05.007","article-title":"Alkylation DNA damage in combination with PARP inhibition results in formation of S-phase-dependent double-strand breaks","volume":"9","author":"ML Heacock","year":"2010","journal-title":"DNA Repair (Amst)"},{"issue":"16","key":"ref38","doi-asserted-by":"crossref","first-page":"15773","DOI":"10.1074\/jbc.M413841200","article-title":"Poly(ADP-ribose) polymerase activity prevents signaling pathways for cell cycle arrest after DNA methylating agent exposure","volume":"280","author":"JK Horton","year":"2005","journal-title":"J Biol Chem"},{"issue":"3","key":"ref39","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1158\/1541-7786.MCR-11-0477","article-title":"Increased PARP-1 association with DNA in alkylation damaged, PARP-inhibited mouse fibroblasts","volume":"10","author":"PS Kedar","year":"2012","journal-title":"Molecular cancer research: MCR"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/1475-2867-11-39","article-title":"Translesion DNA synthesis in the context of cancer research","volume":"11","author":"PA Knobel","year":"2011","journal-title":"Cancer cell international"},{"issue":"2","key":"ref41","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.cell.2010.03.012","article-title":"53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks","volume":"141","author":"SF Bunting","year":"2010","journal-title":"Cell"},{"issue":"8","key":"ref42","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1073\/pnas.1013715108","article-title":"Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells","volume":"108","author":"AG Patel","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"ref43","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1038\/nsmb.1831","article-title":"53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers","volume":"17","author":"P Bouwman","year":"2010","journal-title":"Nat Struct Mol Biol"},{"issue":"3","key":"ref44","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/ncb2201","article-title":"53BP1 nuclear bodies form around DNA lesions generated by mitotic transmission of chromosomes under replication stress","volume":"13","author":"C Lukas","year":"2011","journal-title":"Nat Cell Biol"},{"issue":"1","key":"ref45","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1083\/jcb.201011083","article-title":"Replication stress induces 53BP1-containing OPT domains in G1 cells","volume":"193","author":"JA Harrigan","year":"2011","journal-title":"J Cell Biol"},{"key":"ref46","doi-asserted-by":"crossref","unstructured":"Kotov IN, Siebring-van Olst E, Knobel PA, van der Meulen-Muileman IH, Felley-Bosco E, van Beusechem VW, et al. Whole genome RNAi screens reveal a critical role of REV3 in coping with replication stress. Molecular oncology. 2014. <comment>doi: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/dx.doi.org\/10.1016\/j.molonc.2014.07.008\" xlink:type=\"simple\">10.1016\/j.molonc.2014.07.008<\/ext-link><\/comment> <object-id pub-id-type=\"pmid\">25113059<\/object-id>.","DOI":"10.1016\/j.molonc.2014.07.008"},{"issue":"4","key":"ref47","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1093\/nar\/gks1442","article-title":"Rev3, the catalytic subunit of Polzeta, is required for maintaining fragile site stability in human cells","volume":"41","author":"A Bhat","year":"2013","journal-title":"Nucleic Acids Res"},{"issue":"10","key":"ref48","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1593\/neo.11828","article-title":"Inhibition of REV3 expression induces persistent DNA damage and growth arrest in cancer cells","volume":"13","author":"PA Knobel","year":"2011","journal-title":"Neoplasia"},{"issue":"5","key":"ref49","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data","volume":"2","author":"E Cerami","year":"2012","journal-title":"Cancer discovery"},{"issue":"47","key":"ref50","doi-asserted-by":"crossref","first-page":"7266","DOI":"10.1038\/sj.onc.1205573","article-title":"Cloning and characterization of the common fragile site FRA6F harboring a replicative senescence gene and frequently deleted in human tumors","volume":"21","author":"C Morelli","year":"2002","journal-title":"Oncogene"},{"issue":"5","key":"ref51","doi-asserted-by":"crossref","first-page":"e677","DOI":"10.1016\/j.ijrobp.2012.01.089","article-title":"Low p53 binding protein 1 (53BP1) expression is associated with increased local recurrence in breast cancer patients treated with breast-conserving surgery and radiotherapy","volume":"83","author":"HJ Neboori","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"ref52","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1158\/1535-7163.MCT-13-0803","article-title":"Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib","volume":"13","author":"J Murai","year":"2014","journal-title":"Molecular cancer therapeutics"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0125482","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T23:20:40Z","timestamp":1748388040000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0125482"}},"subtitle":[],"editor":[{"given":"Robert W","family":"Sobol","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2015,5,12]]},"references-count":52,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2015,5,12]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0125482","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,5,12]]}}}